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Abstract
BACKGROUND AND AIMS: Genomewide expression
profiling has identified a number of genes expressed
at higher levels in colorectal cancer (CRC) than in
normal tissues. Our objectives in this study were: 1)
to test whether genes were also distinct on the pro-
tein level; 2) to evaluate these biomarkers in a series
of well-characterized CRCs; and 3) to apply hierarchi-
cal cluster analysis to the immunohistochemical data.
METHODS: Tissue microarrays (TMAs) comprising 351
CRC specimens from 270 patients were constructed
to evaluate the genes Adam10, CyclinD1, AnnexinII,
NFKB, Casein-kinase-2-beta (CK2B), YB-1, P32, Rad51,
c-fos, IGFBP4, and Connexin26 (Cx26). In total, 3,797
samples were analyzed. RESULTS: Unsupervised hi-
erarchical clustering discovered subgroups of CRC
that differed by tumor stage and survival. Kaplan-
Meier analysis showed that reduced Cx26 expression
was significantly associated with shorter patient sur-
vival and higher tumor grade (G1/G2 vs G3, P = .02),
and Adam10 expression with a higher tumor stage
(pT1/2 vs pT3/4, P = .04). CONCLUSIONS: Our study high-
lights the potential of TMAs for a higher-dimensional
analysis by evaluating serial sections of the same tis-
sue core (three-dimensional TMA analysis). In addi-
tion, it endorses the use of immunohistochemistry
supplemented by hierarchical clustering for the iden-
tification of tumor subgroups with diagnostic and
prognostic signatures.
Neoplasia (2005) 7, 741–747
Keywords: Connexin26 (Cx26 ), Adam10, colorectal cancer (CRC), hier-
archical clustering, tissue microarray (TMA).
Introduction
Cancer of the colon and rectum is the second most preva-
lent cause of cancer deaths in men and the third most
common in women [1]. Postoperative adjuvant chemo-
therapy improves outcome in stage III (Dukes stage C)
colon cancer and is now widely accepted as standard
therapy [2,3]. Many patients with stage II (Dukes stage B)
disease are considered to be at high risk for recurrence
and receive adjuvant therapy, although its benefit in such
cases is uncertain. Markers that reliably predict survival are
needed [2,4,5]. These biomarkers should support the clinical
treatment of neoplastic processes (e.g., in selecting specific
drug regimens).
Genomewide expression profiling has identified a number of
genes expressed at higher levels in colorectal cancer (CRC)
than in normal tissue, representing excellent candidates for
diagnostic immunohistochemistry. Tissue microarrays (TMAs)
can be used to test the prognostic significance of antibodies
against proteins encoded by differentially expressed genes
using large numbers of archival patient specimens. Our objec-
tives in this study were: 1) to test whether genes found to be
differentially expressed in CRCs by cDNA expression profiling
were also distinct on the protein level; 2) to evaluate these
potential immunohistochemical markers in a series of well-
characterized CRCs including primary and metastatic tumors;
and 3) to apply hierarchical cluster analysis to the semi-
quantitatively scored data and to determine whether the panel
of markers allows a meaningful grouping of CRCs.
Materials and Methods
Tissue Array Construction
Two TMAs containing 351 samples from 270 patients were
constructed. Tissue samples originated from surgical resec-
tions at the Department of Surgery of the Charite´. On each
TMA, six noncancerous normal mucosa specimens were in-
cluded. The tumor collective and its clinicopathologic data are
summarized in Table 1. One 0.6-mm core was taken from a
representative area of the tumor and inserted into a recipient
paraffin block to create the TMA [6]. We investigated serial
slides cut consecutively and examined the same tumor region
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in three dimensions (Figure 1A). The investigation of one
marker represents a two-dimensional (2D) analysis; addi-
tional sections can be viewed as a three-dimensional (3D)
analysis of the tissue core in which each marker constitutes
another dimension of evaluation. In total, 3797 specimens of
colorectal tissue, including normal mucosa, were evaluated.
Immunohistochemistry
Commercial available antibodies against Adam10, Cyclin-
D1, IGFBP4, NFKB, AnnexinII, Casein kinase 2 beta (CK2B),
Rad51, YB-1, P32, c-fos, and Connexin26 (Cx26 ) were pur-
chased. Antibody sources and staining conditions, including
antigen retrieval methods, are summarized in Table 2. The
genes were chosen in the following ways: first, by personal
communication from collaborators who performed cDNA
microarray analysis on primary and metastatic CRC; second,
by review of the literature [7,8]; and, third, by the suitability of
commercially available antibodies. Except for Cx26, only
upregulated genes were investigated. Antigen retrieval was
performed in a pressure cooker by boiling for 5 minutes then
incubating for 25 minutes in a citrate buffer. Slides were
stained manually using the Dako ChemMate TM Detection
Kit Alkaline Phosphatase/Red Code No. K 5005 (Dako,
Corporation Hamburg, Germany) following manufacturer’s
instructions. Dako Tris-buffered saline (TBS) was used as a
washing buffer. For all antibodies, immunostaining of the
cells was evaluated and scored semiquantitatively: (9) unin-
terpretable (missing spot, no tumor cells, or uninterpretable
staining); (0) negative; (1+) weak; (2+) moderate; and (3+)
strongly positive.
Hierarchical Clustering Analysis
Hierarchical clustering analysis of our TMA data was
performed using the Cluster and TreeView software tool pro-
grams that were originally developed for analyzing cDNA
microarray data (Gene Cluster 3.0 by Michel de Hoon). Clus-
ter and TreeView software are freely available programs
that can be accessed at http://rana.lbl.gov/EisenSoftware.
htm. An Excel macro was designed for converting raw TMA
staining data from a workbook with multiple worksheets in
Excel into a tabular format compatible for use with Gene
Cluster. Average linkage hierarchical clustering [9] was
then performed on the reformatted data using the Cluster
software, with filters set to require at least 80% interpret-
able immunostaining data for each specimen (n = 190) of
13 immunohistochemical evaluation methods (2470 datasets).
Hierarchical clustering was carried out in two dimensions:
tumors were grouped together based on the relatedness of
their immunostaining profile, and antibodies were grouped
based on which tumors they stain. The output was visualized
using TreeView, which graphically displays the results of the
cluster analysis as dendrograms and arrays, wherein the rows
and columns correspond to the raw staining data, presented in
the order determined by hierarchical clustering.
Statistical Analysis
Fisher’s exact test was used to determine the strength of
association between the investigated parameters. P V .05
was considered significant. All calculations were performed
on a PC using the statistical software package SPSS
(Munich, Germany). Clinicopathologic parameters includ-
ing follow-up were available for all specimens with a mean
Table 1. Cases Used for TMA.
Number of specimens 351









Normal colon mucosa 6
Figure 1. (A) Illustration of the 3D analysis of a tumor using TMAs. By
sectioning one core, adjacent areas of a carcinoma potentially representing
the same tumor cell clone are analyzed for multiple markers. (B) Examples of
the immunohistochemical assessment of Cx26 staining in CRCs using TMAs.
Negative staining of tumor cells (0), weakly positive (1), moderately positive
(2), and strongly positive (3) (original magnification, 50 magnification). (C)
Kaplan-Meier plot comparing disease-specific survival in patients with Cx26-
positive colorectal tumors (n = 178) and patients with Cx26-negative tumors
(n = 124) (P = .02). (D) Kaplan-Meier plot comparing disease-specific survival
in cluster 1 ‘‘high tumor stage cluster’’ and cluster 2 ‘‘shorter survival cluster’’
(P = .039).
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follow-up period of 108 weeks. The differences of the Kaplan-
Meier survival curves were tested for statistical significance
with the log rank test, and the 95% confidence intervals were
calculated. For each tumor specimen, the date of operation,
date of last follow-up, and vital status at last follow-up (i.e.,
living or deceased) were recorded. Disease-specific survival
was calculated.
Multivariate analyses were performed with a proportional
hazard model (i.e., Cox regression), and stepwise backward/
forward procedures provided by SPSS software were used
to reduce the number of variables in the Cox models. For
assessing and comparing the Cox models, a Wald test with




In total, immunohistochemical data from 3797 colorec-
tal tissue spots of CRC and normal colon mucosa were
acquired using 11 different antibodies. The normal colon
mucosa samples showed no relevant staining for all inves-
tigated genes except for Cx26, for which we observed a
weak cytoplasmic staining in two of six cases. Sometimes
the mucin of the goblet cells was stained, but we did not
consider this as specific staining. The results of the entire
tumor collective and all antibodies are summarized in Table 3.
The expression was scored semiquantitatively by a four-
tier scale (0—negative, 1—weak, 2—moderate, 3—strongly
positive; Figure 1B) for the clustering analysis. This was
reduced to a two-tier system (0/1—negative, 2/3—positive)
for the independently performed statistical analysis of
single genes and their correlation with clinicopathologic
parameters including survival (Figure 1C). For the markers
YB-1 and CK2B, nuclear and cytoplasmic stainings were
evaluated independently.
Hierarchical Clustering Analysis of TMA Immunostains
An unsupervised hierarchical clustering algorithm allowed
us to cluster the specimens on the basis of their similarities
measured over the 13 immunohistochemical evaluations.
Requiring 80% interpretable immunostaining results for each
specimen, in total, 2470 data points were included in the
analysis. The expression of the antibodies was clustered on
the basis of their similarities measured over the group of
190 tumors (Figure 2). In dendrograms shown in Figure 2,
the length and subdivision of the branches display the re-
latedness of the colorectal tumors (left) and gene expres-
sions (top). Unsupervised hierarchical clustering was able to
distinguish colorectal specimens in four groups (Figure 2A).
As expected, the normal tissue showed a separate cluster
(bottom). The other tumors were divided into three clusters
on the basis of this set of antibodies. For each of the anti-
bodies indicated at the top of the figure, strong positive stain-
ing is indicated by a red square, moderate positive staining in
dark brown, weak staining by light brown, absence of stain-
ing as black, and no available data as grey.
Tumor group 1 was dominated by an increased Adam10
and IGFBP4 expression, whereas no nuclear CK2B staining
was detectable (Figure 2B). Within this subgroup, 85% of
cases showed either pT3 or pT4 tumor stage. Tumor group 2
showed lower levels of Cx26, Adam10, and IGFBP4 ex-
pressions than group 1 tumors, whereas nuclear CK2B was
similarly negative (Figure 2C). In contrast, group 3 tumors
were essentially distinguishable by the positive nuclear
expression of the CK2B antigen.
Immunohistochemistry and Clinicopathologic Parameters
Survival analysis Exploratory analysis was conducted to
correlate the outcome of patients monitored during the
809-week period with the immunohistochemistry results.
The analysis was restricted to disease-specific survival and
Table 2. Antibodies for Immunohistochemistry.
Antigen Product Number Supplier Dilution Pretreatment
Adam10 Sc-16523 Santa Cruz Biotechnology (Santa Cruz, CA) 1:1000 Microwave
Annexin II Sc-9061 Santa Cruz Biotechnology 1:200 Microwave
CK2B Sc-12739 Santa Cruz Biotechnology 1:50 Microwave
Cyclin D1 18-0220 Zymed Laboratory, Inc. (South San Francisco, CA) 1:50 Microwave
NFKB Sc-8008 Santa Cruz Biotechnology 1:400 Microwave
IGFBP4 AF-804 R&D Systems, Inc. (Minneapolis, MN) 1:50 Microwave
c-fos Ab-3 Merck Biosciences, GmbH (Darmstadt, Germany) 1:50 Microwave
Rad 51 NA71 Merck Biosciences, GmbH 1:200 Microwave
YB-1 Polyclonal, peptide-specific Biogenes (Berlin, Germany) 1:50 Microwave
P32 Polyclonal, peptide-specific Biogenes 1:200 Microwave
Cx26 CX-12H10 Zymed Laboratory, Inc. 1:100 Microwave
Table 3. Investigated Specimens with Immunohistochemical Results.
Evaluation Method All Evaluated Specimens (n = 3791)
Low (n = 1924) High (n = 1867)
n % n %
Cx26 124 41 178 59
Adam10 90 28 236 72
Annexin II 140 44 177 56
CK2B cytoplasm 100 33 206 67
CK2B nuclear 245 80 61 20
Cyclin D1 207 60 138 40
NFKB 135 45 167 55
IGFBP4 173 79 46 21
Rad 51 67 27 180 73
YB-1 cytoplasm 255 86 43 14
YB-1 nuclear 158 53 139 42
P32 cyt 106 32 221 68
c-fos 124 62 75 38
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was performed on all specimens. Overexpression (scores 2+
and 3+) of Cx26 was found in 124 (41%) specimens. A total
of 178 (59%) exhibited no relevant Cx26 staining (scores
0 and 1+). The corresponding survival curves according
to Cx26 expression are shown in Figure 1C. The median
survival time of the patients was 194,68 weeks. Statistical
analysis showed that patients with high Cx26 expression
tumors had significantly longer survival rates than patients
with low Cx26 expression (P = .02). All other investigated
antigens showed no prognostic relevance (P > .05). Com-
paring the cluster group 1 with the cluster group 2 in all
investigated samples, we could demonstrate a significant dif-
ference (P = .039) with shorter survival in cluster 2 (Figure 1D).
TNM parameters Cx26 overexpression (scores 2+ and
3+) was significantly linked to G1/G2 tumors when compared
to G3 carcinomas (P = .026). Adam10 overexpression
was linked to a higher tumor stage (pT1/2 vs pT2/3, P = .04).
No other significant correlation with antibody expression
could be demonstrated. The significant results of Cx26 and
Adam10 are summarized in Table 4. When performing
multivariate analysis comparing Cx26 with the parameters
tumor stages (pT), grading (G), and nodal stage (pN), Cx26
was not an independent parameter. However, excluding the
grading and the tumor stage, Cx26 was an independent
factor in multivariate analysis and showed a higher signifi-
cance (P = .022) than nodal status (pN0 vs pN1/2).
Figure 2. (A) Hierarchical cluster analysis of CRC TMA immunostaining results. For each of the antibodies indicated at the top of the figure, strong positive staining
is indicated by a red square, moderate staining by a light brown, weak positive staining by dark brown, absence of staining as black, and no available data as grey.
The dendogram at the top shows the clustering of antibodies based on the relatedness of tumors stained by each antibody. The dendogram on the left side shows
the clustering of the tumors based on the degree of similarity of their immunohistochemical staining results. (B) Enlarged portion from the so-called ‘‘high tumor
stage cluster’’ with prominent Adam10 staining (see vertical line). (C) Enlarged portion of the ‘‘shorter survival stage cluster’’ with prominently reduced Cx26
staining (see vertical line). Number and different colors: cluster group 1 (green), cluster group 2 (red), cluster group 3 (blue), cluster group 4 normal tissue (black).
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We could find differences between the primary tumor
and the metastases from the same patient, but the percent-
age was very low (e.g., regarding Cx26, we found from
55 paired samples the same expression pattern of Cx26
in the primary tumor and metastases in 41 patients, a nega-
tive expression in metastases and a high expression in
the primary tumor in eight patients, and a positive expres-
sion in the primary tumor and a negative expression in
metastases in six patients). The differences were not sig-
nificant in the Wilcoxon test (P = 0.79), especially suited for
paired samples.
The comparison between proximal (cecum, colon ascen-
dens, and colon transversum) and distal carcinomas (rec-
tum, sigma, and colon descendens) showed a significant
correlation with positiveNFKB carcinomas in distal colorectal
tumors (P = .032).
Typical expression patterns of individual genes are avail-
able as supplementary data on the publisher’s web site
and our Berlin-TMA web portal (http://pathoweb.charite.
de/tmaportal).
Discussion
This study is the first comprehensive and the largest analysis
of different immunohistochemical biomarkers associated
with clinicopathologic parameters in CRCs using the synergy
of TMA and hierarchical clustering. We were able to inves-
tigate 3797 specimens. As a result, new biomarkers in the
progression of CRC were detected.
In the past, whole mount sections were used to validate
new biomarkers. They have the advantage of providing
an overview on a larger tumor area, thus enabling particu-
larly the evaluation of the presence and extent of hetero-
geneity in protein expression within a carcinoma. The major
disadvantage, however, is the large amount of tissues, re-
agents, and labor that is needed for the investigation of only
one marker. Similarly, the identification and evaluation of a
specific tumor area within a whole mount section are cum-
bersome. The problem of expression heterogeneity can be
compensated by the analysis of a large tumor collective
and the use of multiple cores representing the same tumor
within a TMA [10]. Furthermore, TMAs provide a simple
mean to analyze adjacent areas by sectioning one core
with a high probability to evaluate tumor cells of the same
clone. In addition to the two dimensions of one TMA spot,
similar tumor cells can be investigated for multiple markers
in a 3D analysis (Figure 1A). Hierarchical clustering and
other statistical means provide an even higher-dimensional
analysis of a tumor collective.
Hierarchical clustering has been so far mainly applied
to expression profiling data, which constitutes a quantita-
tive numerical measure on the amount of mRNA within a
tumor. Immunohistochemical data are, on one hand, simpler
because the expression level can only be scored semi-
quantitatively; on the other hand, it is far more sophisticated
because it visualizes the complexity of protein expression
between different cell types (e.g., tumor versus stromal cells)
and cell compartments (e.g., cytoplasmic, nuclear, and mem-
branous). Only a few studies combined TMA technology
and hierarchical clustering [11–13] so far using a three-tier
(absent, weakly, and strongly positive) as well as a four-tier
system similar to ours. There are yet no clear criteria and final
arguments to favor one or the other system [14]. We were
mainly influenced by conventional practice (i.e., scoring of
HER/NEU2 expression in four scales) and the view that one
additional grade may enhance the semiquantitative represen-
tation of the protein level. Further studies will demonstrate
whether a three-tier or a four-tier system is advantageous. We
evaluated only tumor cell expression and scored cytoplasmic
and nuclear staining independently for two markers.
The synergy of hierarchical clustering and TMA immuno-
histochemistry (i.e., the combination of a high-throughput
technology with an elegant statistical method) carries the
potential to improve our understanding of immunoprofiles
and gene signatures. Unsupervised hierarchical clustering
allowed us to subgroup 190 CRC specimens on the basis of
their similarities in 13 gene expressions (Figure 2). Hierar-
chical clustering was able to distinguish colorectal speci-
mens in four groups. As expected, the normal tissue showed
a separate cluster (bottom) for the upregulated genes. The
other tumors were divided into three clusters on the basis of
this set of genes. Notably, in the upper cluster, 85% of the
tumors are pT3/4 carcinomas, which thus represents a ‘‘high
tumor stage cluster.’’ This cluster is supported by a high
Adam10 staining, which is significantly correlated with a
higher tumor stage. In the second cluster, the so-called
‘‘shorter survival cluster,’’ 79% of the patients survived for
shorter than 200 weeks and a relatively high percentage of
the patients (39%) carried high-grade tumors (G3), which is
represented by the prominently reduced Cx26 staining. The
third cluster is distinguished by the high nuclear CK2B
expression. Until now, the role of CK2B in carcinogenesis
remains unclear. The CK2B overexpression in the cytosol is
Table 4. Immunohistochemical Results with Cx26 and Adam10 in CRC.









Primary tumor 43 71 33 85
Metastasis 81 107 57 151
Liver 22 26 17 36
Lymph nodes 35 43 19 71
Abdominal wall 12 24 10 29
Lung 7 10 9 7
Bone 0 1 0 1
Stage (P = .04)
pT1/2 19 101 8 82
pT3/4 32 145 42 190
Tumor differentiation
(P = .026)
G1/G2 77 32 58 23
G3 141 31 167 60
Nodal status
pN0 16 104 14 5
pN1/2 33 137 39 186
Metastasis
M0 42 81 29 60
M1 73 104 89 146
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clustered together with Adam10, Cx26, and NFKB, which
might be of biologic relevance. However, the overall number
of tumors within this cluster is relatively low (n = 36) and the
results should thus be interpreted cautiously.
To the best of our knowledge, this is the first study
showing that reduced Cx26 expression is significantly asso-
ciated with a shorter patient survival and with a higher
grading of CRC. Interestingly, our results are in accordance
with observations in human bladder, breast, and lung carci-
nomas in which Cx26 expression was found to be reduced
[15,16]. The Cx26 gene was previously isolated as a candi-
date tumor-suppressor gene for breast cancer [15,17]. Con-
nexins are a family of transmembrane proteins that enable
gap junctional intercellular communication (GJIC), which
mediates the transfer of ions, metabolites, and small regu-
latory molecules between cells [18]. Gap junctions, special-
ized clusters of intercellular channels, allow adjacent cells to
directly share ions and hydrophilic molecules of up tof1 kDa
in size [19]. This process, known as GJIC, is thought to con-
trol homeostasis and coordination of cellular activities in both
excitable and nonexcitable tissues [20]. In all, 20 human
connexin genes have been identified so far, usually classified
by their molecular weight, ranging between 25 and 62 kDa
in size [21].
One of the longstanding interests in the field has been the
role of GJIC in carcinogenesis. There is substantial evidence
that GJIC and/or connexins may act as tumor suppressors
[16]. Reduced or aberrant GJIC or connexin expression has
been found in many tumors and tumor cell lines [22,23]. Res-
toration of GJIC in tumor cell lines by connexin transfection
can reduce growth and tumorigenicity [24–27]. Cx32-null
mice have an increased incidence of hepatocarcinogenesis
[28], whereas fibroblasts derived from Cx43-null mice display
increased growth rate, loss of cell adhesion, altered mor-
phology, and other properties associated with a transformed
phenotype [29]. Recently, identical mutations in Cx26 have
been shown to underlie the keratitis– ichthyosis–deafness
(KID) [30] and hystrix-like ichthyosis–deafness (HID) syn-
dromes [31,32], and these patients have an increased
incidence of squamous cell carcinoma (SCC). In vitro trans-
fection of connexin in HeLa and breast cancer cells signifi-
cantly reduces cell growth both in vitro an in vivo [24, 32].
Overexpression of another candidate gene, Adam10,
showed significant correlation with a higher tumor stage.
The ‘‘a disintegrin and metalloprotease’’ (ADAM) family
contributes to the regulation of cell–cell and cell–matrix
interactions that are critical determinants of malignancy.
The recently discovered ADAM family of proteins is unique
in that the members have the potential to regulate both
extracellular matrix remodeling and cell migration [33,34].
Some ADAM proteins interact with integrins and thus may
also play a role in metastasis of cancer cells. In fact, ex-
pression of some ADAM proteins is increased in malignant
cell populations [35,36], including cells obtained from pan-
creatic and hepatocellular carcinomas [37,38] and from
breast cancers [39]. In one of our former studies, we asso-
ciated the overexpression of the chromosomal region at
15q22–23 with a shorter patient survival and tumor progres-
sion [40,41]. Interestingly, the Adam10 gene is located in
this region.
In conclusion, we show in this study that reduced Cx26
expression in CRC is significantly associated with shorter
patient survival and a higher tumor grade, and that Adam10
is correlated with a higher tumor stage. Furthermore, we
were able to show that hierarchical clustering of TMAs is a
useful, promising, and very powerful tool for further inves-
tigations, and will lead us to a diagnostic and prognostic
signature of different carcinomas.
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